303 Wyman Street
Eloxx is a clinical-stage biopharmaceutical company committed to treating patients suffering from rare and ultra-rare diseases caused by Premature Termination Codon (PTC) nonsense mutations.
The company is led by a management team experienced in the development of rare disease therapeutics. All of us at Eloxx share the same goal: to bring safe and effective therapies to the children and adults who need them, as quickly as possible.
Founder and CEO: Dr. Silvia Noiman
CSO: Dr. Shmuel Tuvia
CMO: Dr. Pedro Huertas
VP, R&D: Dr. Dori Pelled
VP, Pharmaceutical Development: Dr. David Reed
Please click here for Eloxx's science.
Please click here for Eloxx's pipeline.